Research programme: cancer therapeutics - RXi Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - RXi Pharmaceuticals

Alternative Names: sd-rxRNA based therapeutics

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RXi Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Gene silencing; PDCD 1 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Jan 2017 MirImmune has been acquired and merged into RXi Pharmaceuticals
  • 02 May 2016 RXi Pharmaceuticals has patent protection for sd-rxRNA® platform in Europe
  • 27 Mar 2015 MirImmune in-licenses Self-Delivering RNAi technology from RXi Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top